Pharming超过了顶线预期;引入了2026财年前景

2026-03-12 14:33

Pharming press release (PHAR): Q4 GAAP EPS of $0.01 in-line.
Revenue of $106.5M (+14.9% Y/Y) beats by $0.6M.
RUCONEST® revenues amounted to US$86.7 million, a 9% increase compared to the fourth quarter of 2024.
Joenja® fourth quarter revenue increased by 53% to US$19.8 million.
Cash generated from operations amounted to US$10.7 million, compared to US$9.3 million in the fourth quarter of 2024.
Cash and cash equivalents, including restricted cash and marketable securities, increased from US$168.9 million at the end of third quarter of 2025 to US$181.1 million at the end of the fourth quarter of 2025.
2026 total revenue guidance of US$405.0 – US$425.0 million (8% to 13% growth) (vs. consnesus of $410.56M), driven by significant and accelerating growth for Joenja® and continued growth for RUCONEST®.

More on Pharming